Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585578 | 0.88 | PTPN11 (0.32) | PRMT5CYP11B2ALDH1A1LRRK2GRM5 | |
| SCHEMBL31382298 | 0.86 | FFAR4 (0.39) | PRMT5CYP11B2CYP3A4ALDH1A1USP2 | |
| SCHEMBL31585176 | 0.81 | ENPP2 (0.37) | CYP11B2ALDH1A1MAPK1LRRK2GRM5 | |
| SCHEMBL30643590 | 0.81 | ADORA2A (0.43) | CYP11B2ALDH1A1MAPK1GRM5SMN1; SMN2 | |
| SCHEMBL24670729 | 0.80 | ENPP2 (0.38) | PRMT5CYP11B2CYP3A4ALDH1A1USP2 | |
| SCHEMBL31382276 | 0.80 | CYP3A4 (0.42) | PRMT5CYP3A4ALDH1A1USP2TP53 | |
| SCHEMBL31062871 | 0.80 | GRM5 (0.41) | CYP3A4ALDH1A1USP2TP53CYP2D6 | |
| SCHEMBL31382136 | 0.80 | ENPP2 (0.38) | PRMT5CYP11B2CYP3A4ALDH1A1USP2 | |
| SCHEMBL30484054 | 0.80 | GRM5 (0.40) | CYP11B2ALDH1A1MAPK1ALKGRM5 | |
| SCHEMBL25831440 | 0.80 | GRM5 (0.40) | CYP11B2ALDH1A1MAPK1ALKGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | PRMT5 2272/4885CYP11B2 3936/4885CYP3A4 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.